NVVI Annual Meeting December 14 & 15, 2022

Dear Immunologists,

It is my great pleasure to invite you to the NVVI-DSI Annual Meeting 2022 that we will host December 14 - 15th. The meeting will take place in our usual location in Noordwijkerhout so that we can meet in person! This will allow us to enjoy a full spectrum of scientific presentations but also enable to (re)connect to friends and collaborators during the social events.

The meeting will comprise presentations from 5 keynote speakers, the van Loghem lecture, 9 invited speakers, Bright-Spark presentations, Thesis award presentation, oral presentations selected from abstracts and posters presentations.

We hope you will join us for the NVVI Annual Meeting 2022 to meet up in person and enjoy Dutch Immunology.

On behalf of the program committee,

Kind regards,
Leendert Trouw
Chair of the program committee

Program

The meeting will comprise presentations from 4 keynote speakers, the Van Loghem lecture, 8 invited speakers, Bright-Spark presentations, Thesis award presentation, oral presentations selected from abstracts and posters presentations.

 

DOWNLOAD the PROGRAM HERE...

 

Keynote speakers:

Muzlifah Haniffa (UK)
Claudia Kemper (USA)
Matteo Iannacone (Italy)
Tim Lämmermann (Germany)

Invited speakers:

Nathalie Cools (University of Antwerp)
Dimitri Diavatopoulos (Radboudumc, Nijmegen)
Bart Everts (LUMC, Leiden)
Mette Hazenberg (AmsterdamUMC)
Tom van der Poll (Amsterdam University Medical Center)
Joost Smolders (Erasmus MC, Rotterdam)
Frank Staal (LUMC, Leiden)
Elisabeth de Vries (University Medical Center Groningen)

KEYNOTE SPEAKERS

Bio Muzlifah Haniffa (UK)
Muzlifah Haniffa is a Wellcome Senior Clinical Research Fellow, Senior Group Leader at the Wellcome Sanger Institute and Professor of Dermatology and Immunology at Newcastle University.
She graduated from medical school in Cardiff, trained as a junior doctor in Cambridge and received her dermatology specialist training in Newcastle. Muzlifah is a Fellow of the Academy of Medical Sciences and a recipient of the Academy of Medical Sciences Foulkes Foundation Medal and the European Federation of Immunological Societies ACTERIA Prize in Immunology and Allergology.
Muzlifah is a leading member of the Human Cell Atlas initiative and pioneered the application of single cell genomics to decode the developing human immune system, and the human skin in health and disease.

Bio Claudia Kemper (USA)
Dr. Kemper is a Senior Investigator and Section Chief at the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Kemper received her Ph.D. in Immunology in 1998 from the University of Hamburg, the Bernhard-Nocht-Institute for Tropical Medicine, in Germany where she worked on the evolutionary aspect of complement regulatory proteins under the supervision of Prof. Irma Gigli. She joined in 1999 John Atkinson’s laboratory as a postdoctoral fellow at Washington University in Saint Louis where she discovered that the complement regulator CD46 is a key checkpoint in human Th1 induction and contraction. Dr. Kemper left Washington University in 2008 as Assistant Professor to move her laboratory to King’s College London, where she was promoted to Associate Professor in 2012 and Full Professor in 2015. During her time at King’s College London, Dr. Kemper’s group discovered that complement activation is not confined, as always thought, to the extracellular space but that it occurs within a broad range of cells. Importantly, this new location of activation allowed her group to discover that intracellular and cell-autonomous complement (coined the complosome) serves unexpected non-canonical roles in cell biology, including the regulation of key metabolic pathways such as glycolysis, oxidative phosphorylation, fatty acid synthesis and cholesterol flux as well as mitochondrial dynamics. Her group further showed that perturbations in complosome functions are associated with a range of human disease conditions, including primary immune deficiency, arthritic diseases (RA, SLE, and scleroderma) and cardiovascular disease. Dr. Kemper’s research at the NHLBI now focusses on the non-canonical roles of complement in cell physiology in health and disease.
Dr. Kemper is the recipient of a Wellcome Trust Investigator Award, the Merit Award for Excellence in Science from the International Complement Society and two Orloff Awards in Science from the NHLBI/NIH. She also serves on the Scientific Board of Apellis, Inc., is the NHLBI representative of the Women Scientists Advisors (WSA), the Head of Admission of the NIH-OXCAM Scholars Program, and the sitting President of the International Complement Society.

Bio Matteo Iannacone (Italy)
Matteo Iannacone obtained a M.D. degree from the University of Milan, Italy, followed by a residency in Internal Medicine and a Ph.D. in Immunology from Vita-Salute San Raffaele University in Milan, Italy. He trained as a postdoctoral fellow at The Scripps Research Institute, La Jolla, CA and at Harvard Medical School, Boston, MA. Since 2010, he directs the Dynamics of Immune Responses Laboratory at the San Raffaele Scientific Institute in Milan, Italy. By combining cutting-edge in vivo imaging techniques and advanced animal models, Matteo has made fundamental contributions to our understanding of the immune response and viral-induced immunopathology. His work has been published in the most important scientific journals (including Nature, Cell, Science, Immunity, Nature Medicine, Nature Immunology) and he holds 14 international patents. He has received numerous awards for his work, including the Armenise-Harvard Foundation Career Development Award, an ERC Starting Grant, the Young Investigator Award from the European Association for the Study of the Liver, the EMBO Young Investigator Award, an ERC Consolidator Grant, the Chiara D’Onofrio Award, an ERC Proof of Concept Grant. He is an elected member of the Henry Kunkel Society and of EMBO. As of November 2022, his work has received more than 9550 citations with an H-index of 44.

Bio Tim Lämmermann (Germany)
Tim Lämmermann is an independent junior group leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, where he heads the research group “Immune Cell Dynamics”. His lab investigates the basic cell biological mechanisms that shape single cell and population dynamics of immune cells in the complexity of inflamed and infected tissues. By using a broad range of microscopy and imaging techniques, his team explores the strategies that cells of the innate immune response have evolved to move individually or in concert with other cells in order to achieve together an optimal immune response.

INVITED SPEAKERS

Bio Nathalie Cools (University of Antwerp)
Nathalie Cools (PhD) is group leader of the Immune Regulation and tolerance-inducing Strategies (IRiS) research group at the Faculty of Medicine and Health Sciences of the University of Antwerp. She obtained her PhD in 2007, after which she held a FWO postdoctoral fellowship. To date, she is appointed with a 60% full professorship at the Faculty of Medicine and Health Sciences from the University of Antwerp, since 2015. Her main research interests focus on immunobiology of human dendritic cells in the pathogenesis of autoimmunity and their modulation in order to provide the prospect for their use to suppress pathogenic immune responses in autoimmunity. Nathalie Cools has a strong background in immunology, including cellular biology and flow cytometry, with a particular emphasis on immune monitoring of experimental human vaccination studies. Nathalie Cools was a member of the Managing Committee of the International COST action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT). She is coordinator of the EU H2020 Restore project https://cordis.europa.eu/project/rcn/213047_en.html and promotor of the EU-EFRO Anicells project (1108, https://www.vlaio.be/nl/andere-doelgroepen/europees-fonds-voor-regionale-ontwikkeling-efro/ontdek-efro-vlaanderen/overzicht) and of two Marie Curie Innovative Training Networks (ITN) funded by the European Union H2020 Programme (https://www.instruct-h2020.eu and https://www.tolerate-horizon.eu). Besides, she is member of the Research Council of the University of Antwerp, vice-president of the Belgian Society for Analytical Cytology, a board member of the Belgian Immunology Society, and an editorial board member of the World Journal of Experimental Medicine, of the Journal of Immunology Research and of the Journal of Molecular Cytotherapy.

Bio Dimitri Diavatopoulos (Radboudumc, Nijmegen)
Dimitri Diavatopoulos performed his PhD studies at Utrecht University and the National Institute of Public Health, investigating how whooping cough bacteria adapted to the human host. After obtaining his PhD degree, he trained as a postdoctoral fellow at the University of Melbourne where he studies how influenza virus infection enhances susceptibility to secondary bacterial infections. He currently heads a research group at the Radboud university medical center, investigating how immune memory to infectious diseases is (re)programmed and maintained during life. His group uses controlled human infection models and systems immunology approaches to unravel the immune processes that drive protection to infection. He is the coordinator of the IMI-2 PERISCOPE project, a public-private consortium aimed at accelerating the development, evaluation and registration of novel pertussis vaccines.

Bio Bart Everts (LUMC, Leiden)
After obtaining his Master’s Degree in 2005 at the University of Amsterdam, specializing on host-pathogen interactions, Bart started his PhD at the department of Parasitology at the Leiden University Medical Center (LUMC). During his PhD he studied the immunomodulatory effects of parasitic worm, Schistosoma, on dendritic cells (DCs). Following his PhD In 2010, he started as a postdoctoral fellow to work in the emerging field of immunometabolism of DCs, macrophages and T cells, in the group of Prof. Dr. E.J. Pearce at the School of Medicine of Washington University, St Louis, Missouri, USA. In 2014, he returned to the department of Parasitology at the LUMC, where he is now an associate professor. With his group he aims to unravel the metabolic underpinnings of the immunoregulatory functions of DCs and macrophages, with the ultimate goal to identify metabolic pathways in these cells that can be targeted to treat hyperinflammatory disease, cancer and to improve vaccine responses.

Bio Mette Hazenberg (Amsterdam University Medical Center and Sanquin Research)
Dr Mette Hazenberg is a Professor in Hematology and Cell Therapy at Amsterdam University Medical Center and Sanquin Research, Amsterdam. Her work as a clinical haematologist and principal investigator is focused on the immunology of allogeneic hematopoietic stem cell transplantation (HCT). Taking advantage of the strong immune responses allogeneic HCT recipients can generate against their malignancies, she identified acute myeloid leukemia (AML) specific antibodies that have great potential as therapeutic antibodies. Donor immune cells can however turn against healthy tissues of the stem cell recipient, resulting in - often devastating - graft versus host disease (GvHD). Hazenberg is working towards a better understanding of the immunological processes underlying the emergence and clinical behaviour of GvHD. Damage to tissues and the microbiome play an important role in GVHD pathophysiology and research in the Hazenberg group is focused on the tissue protective roles of innate lymphoid cells (ILC) and the microbiome and employment thereof to prevent and treat GvHD. She has been awarded several prestigious grants, including a Netherlands Organisation for Scientific Research (NWO) Clinical Fellowship, a Landsteiner (LSBR) Fellowship and NWO Talent Scheme VIDI and Aspasia grants. She is among others member of the National Institute for Public Health (RIVM) working group on COVID-19 vaccination in immunocompromised patients.

Bio Tom van der Poll (Amsterdam University Medical Center)
Tom van der Poll is Professor of Medicine and Chair of the Department of Medicine in the Amsterdam University Medical Center. Van der Poll is board certified in Internal Medicine and Infectious Diseases. His training included a postdoctoral research fellowship in Cornell University Medical College in New York (1993-1995). His research focuses on pneumonia and sepsis, particularly on pathogenesis, the host response, immunotherapy and biomarkers. He is the former chair of the International Sepsis Forum, and was a member of international committees that established the new sepsis definitions (JAMA 2016). In 2019 he was elected as member of the Royal Netherlands Academy of Arts and Sciences.

Bio Joost Smolders (Erasmus MC, Rotterdam)
Joost Smolders obtained his MD and PhD degrees cum laude at Maastricht University Medical Center, the latter on the topic of vitamin D and T cells in multiple sclerosis (MS). Subsequently, he investigated vitamin D metabolism in the central nervous system and started a research line on the isolation and characterization of viable human brain lymphocytes as post-doc at the Neuroimmunology research group of the Netherlands Institute for Neuroscience (NIN) in Amsterdam. He continued this work during his clinical neurology training, and after registering as neurologist (Canisius Wilhelmina Hospital, Nijmegen). In 2019 he was recruited to head MS center ErasMS of Erasmus Medical Center in Rotterdam. In 2022, he was appointed Associate Professor at the departments of Neurology and Immunology. Additionally, he holds a position as visiting staff-member at NIN. His main research interests are translational clinical/ pathological research on immune surveillance in, as well as genetic and environmental determinants of MS.

Bio Frank Staal (LUMC, Leiden)
Prof Dr Frank J.T. Staal obtained his bachelor and master degrees (both cum laude) in Medical Biology at Utrecht University. He obtained his PhD degree (1993) at the Department of Genetics, Stanford University School of Medicine under the supportive guidance of professors Leonard and Leonore Herzenberg where was taught the intricacies of flow cytometry. His thesis dealt with transcriptional regulation of HIV expression in T-lymphocytes and involved many functional flow cytometric assays and cell sorting experiments. In 1993 he became postdoctoral fellow at the Netherlands Cancer Institute for 2 years, after which he moved back to Utrecht University as fellow of the Royal Academy of Sciences (KNAW) in the laboratory of professor Hans Clevers. In 2000 he was recruited to Erasmus Medical Center (EMC) Rotterdam to start his own laboratory on human T cell development and became assistant professor. In 2004 he was appointed associate professor at EMC and expanded his research to Wnt signalling in blood stem cells and T cells, as well as to gene therapy for immune disorders. In 2007 he was recruited to the Leiden University Medical Center (LUMC) and became full professor of Molecular Stem Cell biology. His current efforts are largely directed at human haematopoiesis and lymphopoiesis with an aim of getting stem cell based gene therapy for RAG1 and RAG2 deficient SCID into clinical implementation.

Bio Elisabeth de Vries (University Medical Center Groningen)
Prof. dr. E.G. Elisabeth de Vries, MD, PhD is Professor of Medical Oncology at the University Medical Center Groningen, Groningen, the Netherlands. She is involved in patient care, teaching, and research. Her focus is on interdisciplinary, translational research, aiming for personalized medicine. She uses imaging techniques to support this. She has received numerous grants. She is chair of the ESMO Cancer Medicine Committee. She is a member of the Royal Academy of Arts and Sciences, she received the European Society of Medical Oncology (ESMO) award and is Fellow of the European Academy of Cancer Sciences.

 

 

Bright Sparks

 Bright Sparks are outstanding early career researchers. In a special session at the NVVI-DSI Annual Meeting 2022 young bright scientists will be put in the spotlight and the ultimate Bright Spark selected. 

Bright Sparks submission criteria
We are pleased to announce to continue our tradition regarding the Bright Sparks plenary session. The aim of this session is to put our young bright talents in the spotlight. PhD students or junior postdoctoral fellows who have completed a cutting edge research project are most welcome to put forward their candidacy. From the list of all candidates, 4 are nominated to give an oral presentation in the auditorium before an audience of peers, after which a designated committee will select the next 'Bright Spark in Immunology', who is entitled to a prize of €500.

Please read the following submission criteria carefully, before submitting your abstract for the ‘Bright Sparks’:

  • You must be the presenting/main author of the abstract
  • You must have been a PhD student or junior postdoctoral fellow (maximally 2 years post-PhD) at the time of the performed research)
  • During the submission process you must indicate that your work should be considered for an ORAL presentation in the ‘Bright Sparks’ session in addition to your regular submission for an ORAL presentation in one of the parallel sessions.
  • You may only nominate a single abstract for the ‘Bright Sparks’ (in the event that you are main author on more than one abstract)
  • You will be required to provide the following additional documents:
    a motivation letter (max 1 page)
    2. a CV (max 2 pages)
    3. a recommendation letter of your PhD supervisor, including his/her email address 

Send it all together by email to the NVVI secretariat (This email address is being protected from spambots. You need JavaScript enabled to view it.).

Deadline submission is October Friday 21st.

In case you are selected for participation in the ‘Bright Sparks’ event, the same abstract will not be selected for oral presentation in another session during the congress. However, in case you are not selected you remain eligible for an oral presentation in the regular parallel sessions.

Van Bekkum thesis award

During the NVVI-DSI Annual Meeting 2022 the annual competition to select the best thesis in immunology will take place. The Van Bekkum Thesis award will be selected by the Thesis Award committee.

The winner 2022 gets the opportunity to present his or her work during a 20 minutes plenary presentation during the Annual meeting in Noordwijkerhout and in addition will receive a reward of 1000 Euro.

For more information: https://www.nvvi-dsi.nl/nvvi-awards/van-bekkum-thesis-award 

Abstract Submission

Abstract Submission guidelines:

On behalf of the Programme Committee, we would like to thank you for your interest in submitting an abstract for the NVVI Annual Meeting 2022. The abstract will be judged on following guidelines. Please read carefully before writing your abstract.

Submission is closed!

1. All abstracts must be submitted in ENGLISH. The language during all scientific sessions will be English.

2. Topic/ submission categories:      

  • Adaptive immunology
  • Autoimmunity & Allergy
  • Clinical-/Medical Immunology
  • Immunometabolomics
  • Infection & Inflammation
  • Innate Immunity
  • Mucosal & other organ specific Immunology
  • Tumor Immunology / Immune Therapy
  1. The following items have to be covered in the abstract (no headings for these paragraphs are required):
    a. Introduction: describe research background, the working definition and/or hypothesis and/or aims.
    b. Methods: applied methods.
    c. Results: please present a summary of the most important results based on sufficient quantitative and statistical data. Statements such as “to be completed” will not be accepted.
    d. Conclusion: please present a conclusion based on the results. Statements like “the results will be discussed” will not be accepted. Please number the conclusions.

    4. All abbreviations have to be written in full and explained upon first use.

    5. Format:
    a. Title: maximum 25 words, provide a short clear title reflecting the content of the abstract, no abbreviations in the title. Use generic names only, no commercial names.
    b. Abstract: maximum 500 words excluding title, authors and affiliations. Please note: it’s NOT allowed to include images in your abstract.

    6. Select your presentation preference: Oral presentation - Bright Sparks: Yes/No or poster presentation. For Brights Sparks submission criteria click HERE.

    Submission is closed.
    Abstracts, submitted after the deadline, will NOT be accepted.

Half November the author will receive notification of acceptance for an oral or poster presentation. The Scientific Programme Committee will decide on acceptance of your abstract. Correspondence on this decision is not possible.

For information and questions please consult the Meeting Secretariat:
Connect MEETings via This email address is being protected from spambots. You need JavaScript enabled to view it. or tel: +31 6 83563952.

Submission is closed!

 

 

Registration

 

 

Tickets

On site

2 days member

€ 270

€ 300

2 days non-member

€ 350

€ 380

Master student 2 days *

€ 175

€ 200

1-day (Wednesday) member

€ 205

€ 225

1-day (Wednesday) non member

€ 230

€ 250

1-day (Thursday) member

€ 145

€ 150

1-day (Thursday) non-member

€ 170

€ 175

Industry professional member

€ 320

€ 370

Industry professional non-member

€ 400

€ 430

*Master students can only register for the conference with permission of their supervisor. When registering, please upload a letter of permission of your supervisor. A maximum of 50 master students will be admitted to the conference on a first come first serve basis!

The registration fee includes: Admission to the meeting, all coffee breaks and lunch and congress dinner on Wednesday.

Cancellation policy

Cancellations and refund requests must be submitted in writing to the NVVI via This email address is being protected from spambots. You need JavaScript enabled to view it.. Cancellations made before November 1st 2022 will be refunded less 30 % to cover administration costs. After this date no refunds will be given. All refunds will be made after the congress.

A name change can be made at no cost.

For more information about registration, please contact the NVVI secretariat: This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Hotel reservation

Your hotel accommodation can be booked directly via the congress venue NH Leeuwenhorst te Noordwijkerhout via following link:

https://www.nh-hotels.com/event/nvvi-2022-hotelkamers

For more information about the hotel booking please contact:

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

General information

Dates
Wednesday 14 & Thursday 15 December 2022

Accreditation
Accreditation will be applied for at the College van Medisch Immunologen.

Language
The conference language will be in English

Venue
The meeting will be held in NH Leeuwenhorst at Noordwijkerhout.
Address:
Langelaan 3, 2211 XT Noordwijkerhout

Bus shuttle service from the train station Leiden CS to the venue NH Leeuwenhorst (on Wednesday and Thursday). Busses will only drive before and after the program.   

A route description can be found HERE

Contact

For more Information about registration, please contact the NVVI secretariat: This email address is being protected from spambots. You need JavaScript enabled to view it. 

For more information on the NVVI Annual Meeting 2022, please contact the Congress secretariat:

image003
Karin Vonk
Tel: 06-83563952
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
www.connectmeetings.nl


   NVVI logo def vrijstaand 350 Dutch Society for Immunology (NVVI)
Meibergdreef 15 - Location AMC - L3-109
1105 AZ Amsterdam - The Netherlands
Email: nvvi@amsterdamumc.nl
 

Log in to your account